Would you offer maintenance lenalidomide or rituximab in a patient with DLBCL transformed from a marginal zone lymphoma in a young, fit patient?
Answer from: Medical Oncologist at Community Practice
No. There is no role for maintenance therapy in aggressive lymphomas (transformed or not). This is based on the assumption that DLBCL is curable and randomized trials evaluating maintenance therapy in de novo disease did not show an improvement in survival (see HOVON Nordic trial). Dedicated trials ...
Sign in or Register to read more